Market Closed -
Nyse
04:00:02 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
3.43
USD
|
-0.29%
|
|
-6.79%
|
+106.63%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,485
|
1,550
|
306.9
|
134.1
|
330.1
|
-
|
-
|
Enterprise Value (EV)
1 |
2,087
|
1,092
|
90.22
|
-20.12
|
199.7
|
241.2
|
330.1
|
P/E ratio
|
-8.49
x
|
-6.73
x
|
-1.93
x
|
-0.56
x
|
-1.82
x
|
-2.17
x
|
-2.51
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
45.7
x
|
1.46
x
|
1.93
x
|
4.25
x
|
3.58
x
|
2.56
x
|
EV / Revenue
|
-
|
32.2
x
|
0.43
x
|
-0.29
x
|
2.57
x
|
2.62
x
|
2.56
x
|
EV / EBITDA
|
-11,628,787
x
|
-5,497,765
x
|
-1,253,468
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-4.61
x
|
-0.66
x
|
0.17
x
|
-1.78
x
|
-2.13
x
|
-3.29
x
|
FCF Yield
|
-
|
-21.7%
|
-152%
|
606%
|
-56.1%
|
-46.9%
|
-30.4%
|
Price to Book
|
7.32
x
|
9.34
x
|
3.49
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
77,619
|
76,754
|
79,934
|
80,781
|
96,226
|
-
|
-
|
Reference price
2 |
32.01
|
20.20
|
3.840
|
1.660
|
3.430
|
3.430
|
3.430
|
Announcement Date
|
3/18/21
|
3/3/22
|
2/28/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.34
|
-
|
33.92
|
209.9
|
69.56
|
77.71
|
92.23
|
128.7
|
EBITDA
|
-
|
-179.5
|
-198.6
|
-71.98
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-219.3
|
-261.7
|
-123.6
|
-166
|
-143.5
|
-142.3
|
-138
|
Operating Margin
|
-
|
-
|
-771.65%
|
-58.9%
|
-238.63%
|
-184.71%
|
-154.25%
|
-107.18%
|
Earnings before Tax (EBT)
1 |
-
|
-246
|
-251.5
|
-154.7
|
-195.4
|
-170.7
|
-163.4
|
-160.4
|
Net income
1 |
-
|
-246.3
|
-230
|
-155.8
|
-240.1
|
-178.8
|
-171.6
|
-161.5
|
Net margin
|
-
|
-
|
-678.2%
|
-74.22%
|
-345.11%
|
-230.01%
|
-186.02%
|
-125.5%
|
EPS
2 |
-2.360
|
-3.770
|
-3.000
|
-1.990
|
-2.940
|
-1.889
|
-1.578
|
-1.366
|
Free Cash Flow
1 |
-
|
-
|
-236.8
|
-137.4
|
-121.9
|
-111.9
|
-113.2
|
-100.4
|
FCF margin
|
-
|
-
|
-698.2%
|
-65.44%
|
-175.25%
|
-144.03%
|
-122.73%
|
-78.03%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/24/20
|
3/18/21
|
3/3/22
|
2/28/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
17.01
|
46.5
|
17.29
|
76.32
|
69.8
|
18.99
|
19.28
|
14.49
|
16.79
|
18.05
|
19.02
|
20.07
|
20.62
|
21.27
|
22.34
|
EBITDA
|
-15.49
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-62.78
|
-40.36
|
-69.41
|
-3.114
|
-10.74
|
-51.57
|
-39.79
|
-37.4
|
-39.98
|
-33.61
|
-36.52
|
-36.85
|
-37.49
|
-35.66
|
-36.06
|
Operating Margin
|
-369.08%
|
-86.81%
|
-401.43%
|
-4.08%
|
-15.38%
|
-271.55%
|
-206.34%
|
-258.08%
|
-238.11%
|
-186.19%
|
-192.01%
|
-183.65%
|
-181.82%
|
-167.64%
|
-161.44%
|
Earnings before Tax (EBT)
1 |
-56.35
|
-17.83
|
-65.32
|
-51.32
|
-20.19
|
-59.69
|
-53.73
|
-47.89
|
-39.87
|
-45.76
|
-41.7
|
-42.04
|
-42.46
|
-44.31
|
-44.81
|
Net income
1 |
-34.38
|
-16.66
|
-64.37
|
-50.61
|
-24.16
|
-59.43
|
-47.12
|
-47.81
|
-85.03
|
-46.61
|
-42.03
|
-42.32
|
-49.6
|
-44.31
|
-44.81
|
Net margin
|
-202.12%
|
-35.83%
|
-372.3%
|
-66.31%
|
-34.61%
|
-312.9%
|
-244.34%
|
-329.86%
|
-506.44%
|
-258.16%
|
-220.99%
|
-210.92%
|
-240.58%
|
-208.31%
|
-200.62%
|
EPS
2 |
-0.4500
|
-0.2200
|
-0.8400
|
-0.6500
|
-0.3000
|
-0.7400
|
-0.5800
|
-0.5800
|
-1.030
|
-0.5600
|
-0.4425
|
-0.4281
|
-0.4831
|
-0.4267
|
-0.4367
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/22
|
5/9/22
|
8/9/22
|
11/8/22
|
2/28/23
|
5/9/23
|
8/8/23
|
11/7/23
|
3/13/24
|
5/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
397
|
459
|
217
|
154
|
130
|
88.8
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-237
|
-137
|
-122
|
-112
|
-113
|
-100
|
ROE (net income / shareholders' equity)
|
-
|
-110%
|
-91.7%
|
-122%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-27.2%
|
-43.9%
|
-63.2%
|
-67.1%
|
-
|
Assets
1 |
-
|
-
|
-
|
573.6
|
546.5
|
283
|
255.7
|
-
|
Book Value Per Share
|
-
|
4.370
|
2.160
|
1.100
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-2.580
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.8
|
3.43
|
0.58
|
3.22
|
4.33
|
4.27
|
3.8
|
Capex / Sales
|
-
|
-
|
10.11%
|
0.27%
|
4.62%
|
5.58%
|
4.63%
|
2.95%
|
Announcement Date
|
4/24/20
|
3/18/21
|
3/3/22
|
2/28/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
3.43
USD Average target price
10
USD Spread / Average Target +191.55% Consensus |
1st Jan change
|
Capi.
|
---|
| +106.63% | 330M | | +11.91% | 118B | | +11.60% | 106B | | -4.68% | 24.28B | | -0.82% | 21.96B | | -10.12% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B |
Bio Therapeutic Drugs
|